SEC Form 4 · accession 0001104659-26-082758
Apogee Therapeutics, Inc. · APGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Thomas Henderson
Officer — Chief Executive Officer · Director
Period of report
Jul 8, 2026
Accepted (ET)
Jul 10, 2026 · 8:00 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001974640
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 8, 2026 | S | 20,000 | $133.63 | D | 995,987 | D | |
| Common Stock | Jul 10, 2026 | G | 75,046 | $0.00 | D | 920,941 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.
- F2The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $133.52 to $133.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund.